Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-09-06 , DOI: 10.1111/dom.14546
Bong Gyu Park ₁ , Gyeong Min Kim ₁ , Hye-Jin Lee ₂ , Jae Ha Ryu ₃ , Dong-Hoon Kim ₂ , Jae-Young Seong ₄ , Soojeong Kim ₅ , Zee-Yong Park ₁ , Young-Joon Kim ₁ , Jaemin Lee ₅ , Jae Il Kim _{1,

3}

Affiliation

To develop more effective and long-lasting antiobesity and antidiabetic therapeutics by employing novel chemical modifications of glucagon-like peptide-1 receptor (GLP-1R) agonists.

中文翻译：